MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.

Stock Information for MediWound Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MediWound Ltd.

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
MediWound to Participate in Two Upcoming Investor Conferences
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.